Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • US Food and Administration

    - PMLiVE

    Lilly announces new study data on Inluriyo in metastatic breast cancer

    The five-year survival rate for metastatic breast cancer is 30%

    - PMLiVE

    Gilead’s Yescarta shows benefits for patients with large B-cell lymphoma

    This is the most common type of non-Hodgkin lymphoma worldwide

    - PMLiVE

    Gilead reports Trodelvy breast cancer trial missed primary survival endpoint

    The drug treatment is being evaluated in several ongoing phase 3 trials

    - PMLiVE

    Lilly reports survival benefit with Verzenio in high-risk early breast cancer

    The findings are based on Lilly’s phase 3 monarchE trial

    - PMLiVE

    Roche’s Itovebi granted EC approval to treat advanced breast cancer patients

    Hormone receptor-positive breast cancer accounts for around 70% of all breast cancer cases

    - PMLiVE

    Researchers uncover promising treatment approach for inherited breast cancer

    The study evaluated chemotherapy followed by a targeted cancer drug in patients before surgery

    - PMLiVE

    Roche’s Perjeta-based breast cancer regimen shows sustained survival benefits

    Approximately 56,800 new breast cancer cases are diagnosed in the UK every year

    - PMLiVE

    AstraZeneca/Daiichi Sankyo share positive phase 3 results for Enhertu in early breast cancer

    Around one in three patients with early-stage breast cancer are considered high risk

    - PMLiVE

    Gilead shares promising phase 3 results for Trodelvy plus Keytruda in aggressive breast cancer

    Triple-negative breast cancer accounts for approximately 15% of all cases of the disease

    - PMLiVE

    AstraZeneca/Daiichi Sankyo’s Enhertu shows promise in first-line HER2-positive breast cancer

    Up to 20% of patients with metastatic breast cancer are affected by HER2-positive disease

    - PMLiVE

    AstraZeneca’s Truqap recommended by NICE to treat advanced breast cancer

    NICE estimates that around 1,100 patients will benefit from the twice-a-day tablet

    - PMLiVE

    AstraZeneca/Daiichi Sankyo’s Datroway approved by EC to treat breast cancer

    Approximately 557,000 people are diagnosed with breast cancer every year in Europe

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links